Systematic review of preclinical CBD effects in canine cancers
Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
Systematic review and meta-analysis of disitamab vedotin efficacy in urothelial carcinoma
Researchers Find Disitamab Vedotin Shows Activity In Bladder Cancer
This systematic review and meta-analysis evaluates disitamab vedotin-based therapy in HER2-negative and HER2-low locally advanced or metasta…
A new review suggests the drug disitamab vedotin might work for some bladder cancer patients with low or negative HER2 levels.
Disitamab vedotin plus PD-1 inhibitor showed high response rates in urothelial carcinoma patients across six centers
New Drug Combo Shows Strong Results for Advanced Bladder Cancer
This retrospective cohort study evaluated disitamab vedotin combined with a PD-1 inhibitor in 132 patients with locally advanced or metastat…
A new drug pairing shrank tumors in 71% of advanced bladder cancer patients, even those with diabetes or kidney problems.
Camrelizumab plus nab-paclitaxel showed modest activity in previously treated advanced urothelial carcinoma patients
New Treatment Extends Life for Bladder Cancer Patients
This multicenter Phase II study evaluated camrelizumab plus nab-paclitaxel in 60 patients with advanced urothelial carcinoma who progressed …
For years, Mark, 64, thought he’d beaten cancer.
Magrolimab plus docetaxel shows limited efficacy in metastatic lung and urothelial cancers
New Drug Combo Fails to Shrink Tough Lung and Bladder Cancers
This cohort study evaluated magrolimab plus docetaxel in patients with metastatic non-small cell lung cancer, small cell lung cancer, and ur…
This study shows that adding a new drug to standard chemotherapy did not help patients with advanced lung or bladder cancer live longer or s…
Review: PD1/PDL1 spatial interactions predict pembrolizumab response in metastatic urothelial carcinoma
New Scan Shows Exactly Which Immune Cells Fight Cancer
This review discusses a proof-of-concept study examining PD1/PDL1 spatial interactions in tumor samples from patients with metastatic urothe…
This new method lets doctors see exactly which immune cells are actually fighting the tumor, not just hanging out nearby.
Neoadjuvant atezolizumab shows spatial biomarker changes in operable urothelial carcinoma patients
How a Bladder Cancer Drug Remodels the Tumor Neighborhood
This single-arm, phase II trial evaluated neoadjuvant atezolizumab in patients with operable urothelial carcinoma.
A bladder cancer drug physically breaks down the walls blocking immune cells in tumors, helping doctors predict which patients will respond …
Research across Cancer
Related studies from across the Cancer family.
Liquid biopsy guides kidney-sparing decisions in upper tract urothelial carcinoma without replacing standard care
Liquid biopsy helps doctors decide on kidney-sparing care for upper tract urothelial carcinoma
This review discusses liquid biopsy-guided kidney-sparing management for patients with upper tract urothelial carcinoma. The authors note th…
A review shows liquid biopsy adds value to kidney-sparing decisions for upper tract urothelial carcinoma but does not replace standard imagi…
Metachronous non-muscle invasive bladder cancer after UTUC has worse recurrence and progression with BCG than primary disease
Doctors found that bladder cancer returning later has higher risk of coming back again
This systematic review and meta-analysis of 1292 patients found that metachronous non-muscle invasive bladder cancer after upper tract uroth…
A large review shows bladder cancer returning after a previous kidney cancer treatment is more likely to grow back. This group also has a lo…
Systematic review of extended versus standard pelvic lymph node dissection in bladder cancer surgery
More Lymph Nodes Removed, Better Survival — But at What Cost?
This systematic review analyzed 993 randomized participants undergoing radical cystectomy for muscle-invasive or treatment-refractory non-mu…
This surgery could help some live longer, but it’s not risk-free.
Meta-analysis finds 3.2% prevalence of germline MMR mutations in patients with upper tract urothelial carcinoma
Study finds 3.2% of upper tract urothelial cancer patients have inherited DNA repair mutations
A systematic review and meta-analysis of 14 studies including 2378 patients with upper tract urothelial carcinoma (UTUC) found a pooled prev…
About 3% of upper tract urothelial cancer patients carry inherited DNA repair mutations that link their cancer to Lynch syndrome and affect …
Renal pelvis tumors show survival advantage over other UTUC sites in NCDB analysis
Study finds kidney pelvis tumors linked to better survival in urinary tract cancer
A retrospective cohort study of 12,300 patients with upper urinary tract urothelial carcinoma from the National Cancer Database found renal …
Patients with kidney pelvis tumors had better survival than those with tumors in other upper urinary tract locations, based on analysis of o…
Questions about urothelial carcinoma
How does disitamab vedotin-based therapy work for metastatic urothelial carcinoma patients?
Disitamab vedotin targets HER2 on cancer cells and delivers a toxin directly, often combined with a PD-1 inhibitor to boost the immune response, showing high response rates in metastatic urothelial carcinoma.
Full answer →Is OPDIVO QVANTIG approved for treating urothelial carcinoma by the FDA?
No, OPDIVO QVANTIG is not FDA-approved for urothelial carcinoma; it is approved for renal cell carcinoma and melanoma only.
Full answer →Can disitamab vedotin be used to treat HER2-negative urothelial carcinoma patients?
Yes, disitamab vedotin shows activity in HER2-negative urothelial carcinoma, but response rates are lower than in HER2-low or HER2-positive disease.
Full answer →What are the response rates for disitamab vedotin plus PD-1 inhibitor in urothelial carcinoma?
Disitamab vedotin plus a PD-1 inhibitor shows high response rates in urothelial carcinoma, with objective response rates of 71% in first-line metastatic disease and 51% in HER2-low/negative populations.
Full answer →